Seminars in Nephrology
Volume 29, Issue 1 , Pages 50-58 , January 2009

Potential Role of Growth Factors With Particular Focus on Growth Hormone and Insulin-Like Growth Factor-1 in the Management of Chronic Kidney Disease

  • Bo Feldt-Rasmussen, MD, DMSc

      Affiliations

    • Department of Nephrology, Rigshospitalet, University of Copenhagen, Denmark
    • Corresponding Author InformationAddress reprint requests to Bo Feldt-Rasmussen, MD, DMSc, Chief of Division of Nephrology P 2132, Rigshospitalet, Blegdamsvej 9, DK 2100 Copenhagen, Denmark
    • ,
  • Meguid El Nahas, PhD, FRCP

      Affiliations

    • Sheffield Kidney Institute, University of Sheffield, Sheffield, UK

References 

  1. United States Renal Data System. United States Renal Data System annual report (Atlas of end-stage renal disease in the United States). Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2006;
  2. Ansell D. Summary of findings in the 2006 UK Renal Registry report (chapter 1). Nephrol Dial Transplant. 2007;22(Suppl 7):vii1–vii2
  3. MedSciNet website. [cited 2008 April]. Available from: http://www.medscinet.se/msn/.
  4. Danish Society of Nephrology website. [cited 2008 April]. Available from: http://www.nephrology.dk/Index.htm.
  5. QuaSi-Niere website. [cited 2008 April]. Available from: http://www.quasi-niere.de/index.php?lang=en.
  6. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2004;41:1–12
  7. Chadban SJ, Briganti EM, Kerr PG, Dunstan DW, Welborn TA, Zimmet PZ, et al. Prevalence of kidney damage in Australian adults: the AusDiab kidney study. J Am Soc Nephrol. 2003;14:S131–S138
  8. Glassock R, Winearls C. An epidemic of chronic kidney disease: fact or fiction. Nephrol Dial Transplant. 2008;23:1117–1121
  9. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164:659–663
  10. Kalantar-Zadeh K, Kopple JD, Block G, Humphreys MH. Association among SF36 quality of life measures and nutrition, hospitalization, and mortality in hemodialysis. J Am Soc Nephrol. 2001;12:2797–2806
  11. Remuzzi G, Perico N, Macia M, Ruggenenti P. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl. 2005;99:S57–S65
  12. Khwaja A, El Kossi M, Floege J, El Nahas M. The management of CKD: a look into the future. Kidney Int. 2007;72:1316–1323
  13. Boor P, Sebeková K, Ostendorf T, Floege J. Treatment targets in renal fibrosis. Nephrol Dial Transplant. 2007;22:3391–3407
  14. Chan W, Valerie KC, Chan JCM. Expression of insulin-like growth factor-1 in uremic rats: growth hormone resistance and nutritional intake. Kidney Int. 1993;43:790–795
  15. Tonshoff B, Schaefer F, Mehls O. Disturbance of growth hormone–insulin-like growth factor axis in uraemia (Implications for recombinant human growth hormone treatment). Pediatr Nephrol. 1990;4:654–662
  16. Rabkin R, Sun DF, Chen Y, Tan J, Schaefer F. Growth hormone resistance in uremia, a role for impaired JAK/STAT signaling. Pediatr Nephrol. 2005;20:313–318
  17. Iglesias P, Díez JJ, Fernández-Reyes MJ, Méndez J, Bajo MA, Aguilera A, et al. Growth hormone, IGF-I and its binding proteins (IGFBP-1 and -3) in adult uraemic patients undergoing peritoneal dialysis and haemodialysis. Clin Endocrinol (Oxf). 2004;60:741–749
  18. Doi T, Striker LJ, Quaife C, Conti FG, Palmiter R, Behringer R, et al. Progressive glomerulosclerosis develops in transgenic mice chronically expressing growth hormone and growth hormone releasing factor but not in those expressing insulinlike growth factor-1. Am J Pathol. 1988;131:398–403
  19. Mahesh S, Kaskel F. Growth hormone axis in chronic kidney disease. Pediatr Nephrol. 2008;23:41–48
  20. Flyvbjerg A. The role of growth hormone in the pathogenesis of diabetic kidney disease. Pediatr Endocrinol Rev. 2004;1(Suppl 3):525–529
  21. Hammerman MR. Insulin-like growth factor I treatment for end-stage renal disease at the end of the millennium. Curr Opin Nephrol Hypertens. 2000;9:5–10
  22. Kopple JD. Dietary considerations in patients with chronic renal failure, acute renal failure, and transplantation. In:  Schrier RW editors. Diseases of the kidney. 8th ed.. Philadelphia: Lippincott Williams & Wilkins; 2006;
  23. Mehls O, Tonshoff B, Blum WF, Heinrich U, Seidel C. Growth hormone and insulin-like growth factor 1 in chronic renal failure—pathophysiology and rationale for growth hormone treatment. Acta Paediatr Scand Suppl. 1990;370:28–34
  24. Mitch WE. Insights into the abnormalities of chronic renal disease attributed to malnutrition. J Am Soc Nephrol. 2002;13(Suppl 1):S22–S27
  25. Ikizler TA, Wingard RL, Hakim RM. Interventions to treat malnutrition in dialysis patients: the role of the dose of dialysis, intradialytic parenteral nutrition, and growth hormone. Am J Kidney Dis. 1995;26:256–265
  26. Haffner D, Schaefer F, Girard J, Ritz E, Mehls O. Metabolic clearance of recombinant human growth hormone in health and chronic renal failure. J Clin Invest. 1994;93:1163–1171
  27. Sun DF, Zheng Z, Tummala P, Oh J, Schaefer F, Rabkin R. Chronic uremia attenuates growth hormone-induced signal transduction in skeletal muscle. J Am Soc Nephrol. 2004;15:2630–2636
  28. Ikizler TA, Hakim RM. Nutrition in end-stage renal disease. Kidney Int. 1996;50:343–357
  29. Mehls O, Ritz E, Hunziker EB, Eggli P, Heinrich U, Zapf J. Improvement of growth and food utilization by human recombinant growth hormone in uremia. Kidney Int. 1988;33:45–52
  30. Garibotto G, Barreca A, Russo R, Sofia A, Araghi P, Cesarone A, et al. Effects of recombinant human growth hormone on muscle protein turnover in malnourished hemodialysis patients. J Clin Invest. 1997;99:97–105
  31. Pupim LB, Flakoll PJ, Levenhagen DK, Ikizler TA. Exercise augments the acute anabolic effects of intradialytic parenteral nutrition in chronic hemodialysis patients. Am J Physiol Endocrinol Metab. 2004;286:E589–E597
  32. Sesmilo G, Biller BM, Llevadot J, Hayden D, Hanson G, Rifai N, et al. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency (A randomized, controlled clinical trial). Ann Intern Med. 2000;133:111–122
  33. Deicher R, Hörl WH. Hormonal adjuvants for the treatment of renal anaemia. Eur J Clin Invest. 2005;35(Suppl 3):75–84
  34. Kinugawa S, Tsutsui H, Ide T, Nakamura R, Arimura K, Egashira K, et al. Positive inotropic effect of insulin-like growth factor-1 on normal and failing cardiac myocytes. Cardiovasc Res. 1999;43:157–164
  35. Cho G, Jeong I, Kim S, Kim M, Park W, Oh D, et al. Effect of growth hormone on cardiac contractility in patients with adult onset growth hormone deficiency. Am J Cardiol. 2007;100:1035–1039
  36. Le Corvoisier P, Hittinger L, Chanson P, Montagne O, Macquin-Mavier I, Maison P. Cardiac effects of growth hormone treatment in chronic heart failure: a meta-analysis. J Clin Endocrinol Metab. 2007;92:180–185
  37. Volterrani M, Manelli F, Cicoira M, Lorusso R, Giustina A. Role of growth hormone in chronic heart failure (Therapeutic implications). Drugs. 2000;60:711–719
  38. Jehle PM, Ostertag A, Schulten K, Schulz W, Jehle DR, Stracke S, et al. Insulin-like growth factor system components in hyperparathyroidism and renal osteodystrophy. Kidney Int. 2000;57:423–436
  39. Fouque D, Peng SC, Shamir E, Kopple JD. Recombinant human insulin-like growth factor-1 induces an anabolic response in malnourished CAPD patients. Kidney Int. 2000;57:646–654
  40. Kopple JD, Brunori G, Leiserowitz M, Fouque D. Growth hormone induces anabolism in malnourished maintenance hemodialysis patients. Nephrol Dial Transplant. 2005;20:952–958
  41. Hansen TB, Gram J, Jensen PB, Kristiansen JH, Ekelund B, Christiansen JS, et al. Influence of growth hormone on whole body and regional soft tissue composition in adult patients on hemodialysis (A double-blind, randomized, placebo-controlled study). Clin Nephrol. 2000;53:99–107
  42. Iglesias P, Diez JJ, Fernandez-Reyes MJ, Aguilera A, Burgués S, Martinez-Ara J, et al. Recombinant human growth hormone therapy in malnourished dialysis patients: a randomized controlled study. Am J Kidney Dis. 1998;32:454–463
  43. Johannsson G, Bengtsson BA, Ahlmen J. Double-blind, placebo-controlled study of growth hormone treatment in elderly patients undergoing chronic hemodialysis: anabolic effect and functional improvement. Am J Kidney Dis. 1999;33:709–717
  44. Jensen PB, Hansen TB, Frystyk J, Ladefoged SD, Pedersen FB, Christiansen JS. Growth hormone, insulin-like growth factors and their binding proteins in adult hemodialysis patients treated with recombinant human growth hormone. Clin Nephrol. 1999;52:103–109
  45. Kotzmann H, Yilmaz N, Lercher P, Riedl M, Schmidt A, Schuster E, et al. Differential effects of growth hormone therapy in malnourished hemodialysis patients. Kidney Int. 2001;60:1578–1585
  46. Feldt-Rasmussen B, Lange M, Sulowicz W, Gafter U, Lai KN, Wiedeman J, et al. Growth hormone treatment during hemodialysis in a randomized trial improves nutrition, quality of life, and cardiovascular risk. J Am Soc Nephrol. 2007;18:2161–2171
  47. Kopple JD, Cheung A, Christiansen JS, Lange M, Wiedemann J, El Nahas M, et al. OPPORTUNITY™: a clinical trial to asses the effects of human growth hormone on outcomes in maintenance hemodialysis patients. Clin J Am Soc Nephrol. 2008;3(6):1741–1751

PII: S0270-9295(08)00170-8

doi: 10.1016/j.semnephrol.2008.10.007

Seminars in Nephrology
Volume 29, Issue 1 , Pages 50-58 , January 2009

Article Tools

* Image Usage & Resolution